Funding for this research was provided by:
Received: 17 August 2018
Accepted: 27 December 2018
First Online: 14 January 2019
Ethics approval and consent to participate
: Trial documentation was approved by institutional review boards at each study site, and all patients provided written informed consent. A full list of the ethics committees and their institutions is provided in Appendix 1 of the Additional file InternalRef removed.
: Not applicable
: CD: Consultant/Advisor: Ipsen; MEP: Consultant/Advisor: Ipsen, Lexicon, Novartis, Pfizer; Research Support: Ipsen, Novartis; PR: Consultant/Advisor: Ipsen; Speakers bureau: Ipsen, Novartis; Research Support: Ipsen, Novartis; Employee: Ipsen (Spouse); AL: Employee: Ipsen; CM: Employee: Ipsen (at the time of work); EB: Received remuneration for services (advisory board or board of directors; corporate-sponsored research; consulting fee; research investigator; speaker) from Ipsen, Novartis, Pfizer, and Advanced Accelerator Applications; MEC: Received honoraria, consultancy and speakers’ bureau fees from Ipsen, Advanced Accelerator Applications, and Novartis.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.